Neutralizing antibody responses to antigenically drifted influenza A(H3N2) viruses among children and adolescents following 2014-2015 inactivated and live attenuated influenza vaccination

Clinical and Vaccine Immunology

Volumn 23, Issue 10, 2016, Pages 831-839

  Levine, Min Z ^a   Martin, Judith M ^b   Gross, F Liaini ^a,e   Jefferson, Stacie ^a   Cole, Kelly Stefano ^b,c   Archibald, Crystal Ann ^b,c   Nowalk, Mary Patricia ^b   Susick, Michael ^b   Moehling, Krissy ^b   Spencer, Sarah ^a,d   Chung, Jessie R ^a,d   Flannery, Brendan ^a   Zimmerman, Richard K ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^e BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; LIVE VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CROSS REACTION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS IMMUNITY; ANTIGENIC VARIATION; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA B VIRUS; INFLUENZA, HUMAN; PRESCHOOL CHILD; SEASON;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SEASONS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84990185693     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00297-16     Document Type: Article

References (46)

1. Li CK, Rappuoli R, Xu XN. 2013. Correlates of protection against influenza infection in humans-on the path to a universal vaccine? Curr Opin Immunol 25:470-476. http://dx.doi.org/10.1016/j.coi.2013.07.005.
2. Reber A, Katz J. 2013. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 12:519-536. http://dx.doi.org/10.1586/erv.13.35.
3. Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, Karron RA, Walter EB, Centers for Disease Control and Prevention. 2014. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 63:691-697.
4. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. 2015. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 64:818-825. http://dx.doi.org/10.15585/mmwr.mm6430a3.
5. Treanor J. 2004. Weathering the influenza vaccine crisis. N Engl J Med 351:2037-2040. http://dx.doi.org/10.1056/NEJMp048290.
6. Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. 6 May 2016. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis http://dx.doi.org/10.1093/infdis/jiw181.
7. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. 2016. Variable influenza vaccine effectiveness by subtype: A systematic review and meta-Analysis of test-negative design studies. Lancet Infect Dis 16:942-951. http://dx.doi.org/10.1016/S1473-3099(16)00129-8.
8. Bedford T, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, Daniels RS, Gunasekaran CP, Hurt AC, Kelso A, Klimov A, Lewis NS, Li X, McCauley JW, Odagiri T, Potdar V, Rambaut A, Shu Y, Skepner E, Smith DJ, Suchard MA, Tashiro M, Wang D, Xu X, Lemey P, Russell CA. 2015. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature 523:217-220. http://dx.doi.org/10.1038//nature14460.
9. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, Skepner E, Lewis NS, Spronken MI, Russell CA, Eropkin MY, Hurt AC, Barr IG, de Jong JC, Rimmelzwaan GF, Osterhaus AD, Fouchier RA, Smith DJ. 2013. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342:976-979. http://dx.doi.org/10.1126/science.1244730.
10. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y. 2015. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season. J Infect Dis 212:726-739. http://dx.doi.org/10.1093/infdis/jiv177.
11. Appiah GD, Blanton L, DMello T, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth DE, Katz J, Jernigan D, Brammer L. 2015. Influenza activity-United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 64:583-590.
12. DMello T, Brammer L, Blanton L, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Finelli L, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth D, Villanueva J, Katz J, Jernigan D. 2015. Update: influenza activity-United States, September 28, 2014-February 21, 2015.MMWRMorb Mortal Wkly Rep 64:206-212.
13. Rolfes M, Blanton L, Brammer L, Smith S, Mustaquim D, Steffens C, Cohen J, Leon M, Chaves SS, Abd Elal AI, Gubareva L, Hall H, Wallis T, Villanueva J, Bresee J, Cox N, Finelli L. 2014. Update: influenza activity-United States, September 28-December 6, 2014. MMWR Morb Mortal Wkly Rep 63:1189-1194.
14. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. 2015. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep 12:1-6. http://dx.doi.org/10.1016/j.celrep.2015.06.005.
15. Haveri A, Ikonen N, Julkunen I, Kantele A, Anttila V, Ruotsalainen E, Nohynek H, Lyytikainen O, Savolainen-Kopra C. 2015. Reduced crossprotection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine. Euro Surveill 20:21028. http://dx.doi.org/10.2807/1560-7917.ES2015.20.5.21028.
16. World Health Organization. 26 February 2015. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/vaccines/virus/recommendations//2015-16-north/en/.
17. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM. 2015. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015. MMWR Morb Mortal Wkly Rep 64:10-15.
18. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B, for the U.S. Flu VE Investigators. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis, in press.
19. Kojimahara N, Maeda A, Kase T, Yamaguchi N. 2006. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 24:5966-5969. http://dx.doi.org/10.1016/j.vaccine.2006.05.009.
20. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355:2513-2522. http://dx.doi.org/10.1056//NEJMoa061850.
21. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. 2009. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 361:1260-1267. http://dx.doi.org/10.1056/NEJMoa0808652.
22. WHO Global Influenza Surveillance Network. 2011. Serological diagnosis of influenza by haemagglutination inhibition testing. In Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization, Geneva, Switzerland.
23. Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S. 2015. Preexisting immunity, more than aging, influences influenza vaccine responses. Open Forum Infect Dis 2:ofv052. http://dx.doi.org/10.1093/ofid/ofv052.
24. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. 2010. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 10:18. http://dx.doi.org/10.1186/1471-2288-10-18.
25. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-777. http://dx.doi.org/10.1017/S0022172400022610.
26. Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, McElhaney JE, Oostvogels L, van Essen GA, Gaglani M, Jackson LA, Vesikari T, Legrand C, Tibaldi F, Innis BL, Dewe W. 2015. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. Open Forum Infect Dis 2:ofv067. http://dx.doi.org/10.1093/ofid/ofv067.
27. Fox A, Mai LQ, Thanh LT, Wolbers M, Hang NLK, Thai PQ, Yen NTT, Hoa LNM, Bryant JE, Duong TN, Thoang DD, Barr IG, Wertheim H, Farrar J, Hien NT, Horby P. 2015. Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection. J Infect 70:187-196. http://dx.doi.org/10.1016/j.jinf.2014.09.003.
28. Tsang TK, Cauchemez S, Perera RA, Freeman G, Fang VJ, Ip DK, Leung GM, Malik Peiris JS, Cowling BJ. 2014. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis 210:684-692. http://dx.doi.org/10.1093/infdis//jiu186.
29. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. 2011. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30:1081-1085. http://dx.doi.org/10.1097/INF.0b013e3182367662.
30. Verschoor CP, Singh P, Russell ML, Bowdish DM, Brewer A, Cyr L, Ward BJ, Loeb M. 2015. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One 10:e0131531. http://dx.doi.org/10.1371/journal.pone.0131531.
31. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A, Daniels R, Hay A. 2010. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: A role in virus attachment? J Virol 84:6769-6781. http://dx.doi.org/10.1128/JVI.00458-10.
32. Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, Aranio D, Branch A, Dong L, Holiday C, Liu F, Steward-Clark E, Sun H, Tsang B, Wang D, Whaley M, Bai Y, Cronin L, Browning P, Dababneh H, Noland H, Thomas L, Foster L, Quinn CP, Soroka SD, Katz JM. 2011. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 49:2210-2215. http://dx.doi.org/10.1128/JCM.00229-11.
33. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le NMH, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N, de Jong JC, Palache A, Beyer WE, Le QM, Nguyen TH, Wertheim HF, Hurt AC, Osterhaus AD, Barr IG, Fouchier RA, Horby PW, Smith DJ. 2014. Antibody landscapes after influenza virus infection or vaccination. Science 346:996-1000. http://dx.doi.org/10.1126/science.1256427.
34. Ross TM, Lin CJ, Nowalk MP, Huang HH, Spencer SM, Shay DK, Sambhara S, Sundaram ME, Friedrich T, Sauereisen S, Bloom CE, Zimmerman RK. 2014. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age. Hum Vaccin Immunother 10:1195-1203. http://dx.doi.org/10.4161/hv.28313.
35. Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH, Hodinka RL, Reyes-Teran G, Ross TM, Wilson PC, Ahmed R, Bloom JD, Hensley SE. 2014. Potential antigenic explanation for atypical H1N1 infections among middle-Aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A 111:15798-15803. http://dx.doi.org/10.1073/pnas.1409171111.
36. Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, Carter DM, Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, Ahmed R, Wilson PC, Hensley SE. 2013. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med 210:1493-1500. http://dx.doi.org/10.1084/jem.20130212.
37. Li J, Arevalo MT, Chen Y, Chen S, Zeng M. 2014. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. Int J Infect Dis 27:37-43. http://dx.doi.org/10.1016/j.ijid.2014.05.016.
38. Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z, Luke C, Treanor J, Subbarao K. 2016. Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9). J Infect Dis 213:922-929. http://dx.doi.org/10.1093/infdis/jiv526.
39. Babu TM, Levine M, Fitzgerald T, Luke C, Sangster MY, Jin H, Topham D, Katz J, Treanor J, Subbarao K. 2014. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32:6798-6804. http://dx.doi.org/10.1016/j.vaccine.2014.09.070.
40. Ilyushina NA, Haynes BC, Hoen AG, Khalenkov AM, Housman ML, Brown EP, Ackerman ME, Treanor JJ, Luke CJ, Subbarao K, Wright PF. 2015. Live attenuated and inactivated influenza vaccines in children. J Infect Dis 211:352-360. http://dx.doi.org/10.1093/infdis/jiu458.
41. Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B. 2016. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis 213:1546-1556. http://dx.doi.org/10.1093/infdis/jiv577.
42. Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM. 2016. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 137:e20153279. http://dx.doi.org/10.1542/peds.2015-3279.
43. Centers for Disease Control and Prevention. 22 June 2016. ACIP votes down use of LAIV for 2016-2017 flu season. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/media/releases/2016/s0 622-laiv-flu.html. Accessed 27 July 2016.
44. Wright PF, Hoen AG, Ilyushina NA, Brown EP, Ackerman ME, Wieland-Alter W, Connor RI, Jegaskanda S, Rosenberg-Hasson Y, Haynes BC, Luke CJ, Subbarao K, Treanor JJ. 2016. Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. Open Forum Infect Dis 3:ofw108. http://dx.doi.org/10.1093/ofid/ofw108.
45. Coelingh KL, Wu XW, Mallory RM, Ambrose CS. 2014. An integrated multi-study analysis of serum HAI antibody responses to Ann Arbor strain live attenuated influenza vaccine in children and adults. Trials Vaccinol 3:150-153. http://dx.doi.org/10.1016/j.trivac.2014.08.001.
46. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM. 2007. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685-696. http://dx.doi.org/10.1056/NEJMoa065368.